A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 326 participants.

Also called NCT06344104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 326 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06344104
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina, Australia, China, Hong Kong SAR China, India, Japan, Philippines, Russia, South Korea, Türkiye, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06344104. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2025-11-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Acronym
BaxAsia
Condition
Uncontrolled Hypertension
Condition
Resistant Hypertension
Intervention (Drug)
Baxdrostat
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06344104
Content hash
5a320150c9b79ca461a9804d5eea4fdbb43d65fc8432662d1ca9ec544181890d